Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,494.80
(
0.73%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.83
(
-0.88%
)
Bitcoin
81,038.87
(
0.68%
)
News Focus
News Focus
Post# of 257553
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122973
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 241842

Friday, 05/06/2022 3:24:03 PM

Friday, May 06, 2022 3:24:03 PM

Post# of 257553
CLVS -31% on negative FDA feedback re Rubraca-monotherapy data in ovarian cancer first-line maintenance setting:

https://endpts.com/that-big-rd-parp-win-clovis-ceo-mahaffy-touted-a-few-weeks-ago-the-fda-isnt-buying-it/

The problem is the FDA isn’t being won over on PFS data, according to Clovis. They want mature OS data — and we find that the agency specified at least 50% mature OS data — which Clovis estimates won’t be available for another 2 years…

I can’t find this information in a CLVS PR or SEC filing, so I presume it came out in some other form.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today